Top virologist says will not take Covaxin until efficacy data is out India s national drug regulator has approved the Covid-19 vaccines of both Serum Institute of India (SII) and Bharat Biotech for restricted use in the country. However, experts have severely criticised the regulator for clearing Bharat Biotech s Covaxin even though the efficacy data is available yet. Noted Indian virologist Gagandeep Kang shares her views in a report in The Hindu. Kang said Bharat Biotech has data from animal challenge studies that are supportive of efficacy, but that doesn t automatically imply human efficacy. From humans, the drugmaker must be following up their Phase I and Phase II participants for safety and immunogenicity and may have some data, but that is not going to be sufficient. Bharat Biotech will need efficacy data from its Phase III trial which may take a few weeks or months to come as the company is still in the process of recruitment, vaccination, and data collection.
Coronavirus Vaccine Updates: From Pfizer to Moderna to Sputnik, a look at major COVID vaccine candidates and their status
Coronavirus Vaccine Updates: As India prepares to launch its vaccine drive on January 16, here is a look at the main COVID-19 vaccines candidates and where they stand now.
Publish Date: Sun, 10 Jan 2021 04:32 PM IST
New Delhi | Agencies: Nearly a year has passed since the beginning of coronavirus pandemic but the hunt to find a vaccine for the deadly pahtogen is still on. Amid this, several countries, including India, have given approval to several vaccine candidates for limited emergency use. In India, Bharat Biotech s Covaxin and Serun Institute of India s Covieshiled have been approved, paving the way to launch the world s largest vaccination against COVID-19 from January 16.
Death of volunteer who took dose of Covaxin not related to vaccine or placebo, says Bharat Biotech
Representational image
The company says that at the time of enrolment, the 42-year-old volunteer in Bhopal had fulfilled all criteria to be accepted as participant in Phase III trial
The volunteer was reported to be healthy in all site follow up calls post seven days of dosing and no after-effects were observed/reported, says the firm
Share Via
Read Full Story
New Delhi: Hyderabad-based Bharat Biotech on Saturday said that the death of a 42-year-old volunteer from Bhopal in Madhya Pradesh who took a dose of ovaxin in the clinical trial of the Covid-19 vaccine was not related to the vaccine or placebo.
COVID-19 vaccine race: Main candidates and where they stand
SECTIONS
Last Updated: Jan 10, 2021, 11:56 AM IST
Share
Synopsis
Co-developed by the University of Oxford and British-Swedish company AstraZeneca and known as Covishield in India, the vaccine was the first on which a scientific study was published based on Phase 3 clinical trials.
AFP
3,029,815.0
Almost a year into the COVID-19 pandemic, about 200 vaccine candidates are in the works and 10 have been either approved by several countries or are under limited emergency use. As India prepares to launch its vaccine drive on January 16, here is a look at the options:
Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, the indigenous vaccine has been granted emergency use authorisation in clinical trial mode by the Indian government.
India s Covid-19 vaccination to begin on Jan 16: When will others be ready?
India
Published: Saturday, January 9, 2021, 19:06 [IST]
New Delhi, Jan 09: Almost a year into the COVID-19 pandemic, about 200 vaccine candidates are in the works and 10 have been either approved by several countries or are under limited emergency use.
Representational Image
As India prepares to launch its vaccine drive on January 16, here is a look at the options:
COVAXIN
Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, the indigenous vaccine was granted emergency use authorisation in clinical trial mode by the Indian government this week.